Group 1 - 康方生物's stock price increased over 4%, reaching a new high of 173.8 HKD, with a trading volume of 1.212 billion HKD [1] - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain, where 康方生物's partner Summit Therapeutics will present the results of the HARMONi study, a pivotal Phase III clinical trial for the PD-1/VEGF bispecific antibody drug [1] Group 2 - UBS has added 康方生物 to its list of major recommended stocks in the Asia-Pacific region, citing the overseas potential of its main asset, Edafo, which is not fully reflected in the stock price [2] - The firm believes that news regarding potential collaborations with multinational companies and the upcoming HARMONi study results will act as positive catalysts for the stock price [2] - UBS raised its peak sales forecast for Edafo from 14.6 billion USD to 16.3 billion USD and for another key asset, Okan, from 2.2 billion USD to 3.4 billion USD, while increasing the target price from 197.5 HKD to 224.3 HKD with a "Buy" rating [2]

Core Viewpoint - 康方生物's stock rose over 4%, reaching 164.6 HKD with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody drug, Ivoris, during the conference, specifically the results from the international multicenter Phase III clinical trial HARMONi, which has been selected for a Late-Breaking Abstract oral presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in patients with immune therapy-resistant lung cancer, which has been included in the Mini Oral session of the conference [1] - The combination therapy of Cardonili has previously been recognized as a breakthrough therapy for advanced squamous non-small cell lung cancer (NSCLC) that has progressed after PD-(L)1 inhibitor treatment, highlighting its significant clinical value [1]

Core Viewpoint - 康方生物's stock rose over 4%, reaching 164.6 HKD, with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody new drug, Ivoris, during the conference, which has been selected for a Late-Breaking Abstract oral presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in the context of immune therapy-resistant lung cancer, which has been included in the conference's Mini Oral session [1] - The combination therapy of Cardonili has been recognized as a breakthrough treatment for advanced squamous non-small cell lung cancer (NSCLC) after progression on PD-(L)1 inhibitors, highlighting its significant clinical value [1]